MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to introduce three new members to its Board of Directors.

MedPharm has announced the appointment of three new members to its Board of Directors following an investment by Ampersand Capital Partners (“Ampersand”) in the Company earlier this year. Two of the new Non-Executive Directors are members of the Ampersand investment team: David Parker, General Partner, and Trevor Wahlbrink, Partner. The third Non-Exective Director appointment is Patrick Walsh, who is currently the CEO of Avista Pharma Solutions, a pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Durham, North Carolina.

All have in-depth experience in the healthcare sector and have served on the boards of multiple CDMO businesses.

‘We are very pleased to have David, Trevor and Patrick joining MedPharm’s board’, stated CEO Andy Muddle. ‘They bring a wealth of experience which will be highly beneficial to MedPharm as it continues its impressive growth. Their wisdom and oversight will be invaluable to the business as we expand globally into new markets’.

new board trevor wahlbrink
new board patrick walsh
David Parker
Trevor Wahlbrink
Patrick Walsh

Notes to editors

About MedPharm
MedPharm Ltd. is a leading, global provider of contract topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through proprietary, industry-leading performance testing models. Well-established as a global leader in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations. These solutions are recognized for their scientific rigor by regulators and investors. MedPharm has fully established R&D centres in the US and U.K. and GMP clinical manufacturing at its global headquarters facility in Guildford, UK.

About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.

Back to News